



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

### ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 11429

**Title:** Promising new treatment targets in patients with fibrosing lung disorders

**Reviewer code:** 00608195

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-05-21 22:46

**Date reviewed:** 2014-06-05 01:30

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

### COMMENTS TO AUTHORS

The article is na interesting review about the new treatments for fibrosing lung disorders. It covers the new recentes developments on this subject and it is well written. Nevertheless, the abstract do not reflect what the authors try to discuss on the article and it should be re-written.

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 11429

**Title:** Promising new treatment targets in patients with fibrosing lung disorders

**Reviewer code:** 00505786

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-05-21 22:46

**Date reviewed:** 2014-06-24 16:50

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

The topic of the review is of great interest. It is a rapidly evolving field. I have several comments 1) The article does not have a Methods section and therefore critical information is lacking. The authors should mention how they performed the literature search and based on which criteria they selected the articles. (provide key words used, number of articles retrieved, databases searches and how articles were selected) 2) The introduction should be expanded. The authors should provide a short overview of the current pathogenetic model for IPF 3) TGFb is a master cytokine in the fibrotic process. Please expand and provide more data on the role of this molecule 4) I do not believe that anti-TNF therapy is an option for CTD-ILD 5) Please add the most recent data on nintedanib (recent NEJM publication) 6) The authors do not mention pirfenidone. This also an interesting novel treatment. There is a recent major publication in NEJM that should be included 7) Ref 33 is a duplicate 8) CTD related ILD should be mentioned in a separate section. This form of ILD has several distinct characteristics. I would suggest to focus on SSc-related ILD. Please provide data on the conventional therapeutic approach (Cyclophosphamide) and novel therapeutic approaches such as MMF and rituximab 9) There are other major pathways involved in the pathogenesis of IPF. The authors should at least briefly mention the role of developmental pathways such as the Wnt pathway. Moreover, please provide some data on the role of epithelial-to-mesenchymal transition in IPF

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 11429

**Title:** Promising new treatment targets in patients with fibrosing lung disorders

**Reviewer code:** 02416403

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-05-21 22:46

**Date reviewed:** 2014-06-25 09:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

This review article on new treatment target in pulmonary fibrosis is well organized and written. I have no criticism on this manuscript.

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 11429

**Title:** Promising new treatment targets in patients with fibrosing lung disorders

**Reviewer code:** 00608190

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-05-21 22:46

**Date reviewed:** 2014-06-29 09:11

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

This review presents potential therapeutic options targeting interstitial pneumonia, especially idiopathic pulmonary fibrosis. Numerous treatment targets are shown in the article, whereas miscellaneous targets are mixed in one section of the manuscript. A better understanding of this article requires the improved composition of the manuscript. In particular, the section of 'plasma membrane' should be modified.